Results 41 to 50 of about 2,313 (149)

Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics

mAbs, 2020
Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the epithelial barrier via engagement of the polymeric ...
Bharathikumar Vellalore Maruthachalam, Adam Zwolak, Xiefan Lin-Schmidt, Edward Keough, Ninkka Tamot, Sathya Venkataramani, Brian Geist, Sanjaya Singh, Rajkumar Ganesan   +8 more
doaj   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Impact of Cistron Topology and Bicistronic Vector Design in the piggyBac Transposon System for Improved Antibody Expression

Biotechnology Journal, Volume 21, Issue 8, August 2026.
Graphical Abstract and Lay Summary In this study, we systematically evaluated bicistronic vector designs within the piggyBac transposon system and identified that dual CMV promoters driving a Light chain‐GS‐Heavy chain configuration deliver optimal monoclonal antibody productivity.
Jason Vitko, Thomas King, Efecan Aral, Steven McLellan, Hope Divello, Sara Maimouni, Tiffany McLamarrah, Jennifer Tedstone, Victor Cairns, Christine DeMaria, John J. Scarcelli   +10 more
wiley   +1 more source

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

mAbs
The development of bispecific antibodies that bind at least two different targets relies on bringing together multiple binding domains with different binding properties and biophysical characteristics to produce a drug-like therapeutic.
Michael Mullin, James McClory, Winston Haynes, Justin Grace, Nathan Robertson, Gino van Heeke   +5 more
doaj   +1 more source

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment

Frontiers in Immunology, 2022
Recombinant antibodies such as nanobodies are progressively demonstrating to be a valid alternative to conventional monoclonal antibodies also for clinical applications. Furthermore, they do not solely represent a substitute for monoclonal antibodies but
Jiewen Wang, Jiewen Wang, Jiewen Wang, Guangbo Kang, Guangbo Kang, Guangbo Kang, Haibin Yuan, Haibin Yuan, Haibin Yuan, Xiaocang Cao, He Huang, He Huang, He Huang, Ario de Marco   +13 more
doaj   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Investigating protein–excipient interactions of a multivalent VHH therapeutic protein using NMR spectroscopy

mAbs, 2022
Multispecific therapeutic proteins come in a variety of formats, including bi- and tri-specific antibodies, dual-variable domain antibodies, and CrossMabs.
Jainik Panchal, Bradley T. Falk, Valentyn Antochshuk, Mark A. McCoy   +3 more
doaj   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, Volume 183, Issue 16, Page 4512-4531, August 2026.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Beyond Sequence: Posttranslational Remodeling of Antigens in Autoimmunity

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Autoimmune responses are often attributed to failed tolerance to self‐proteins, yet protein expression alone cannot explain why certain antigens dominate disease, why autoreactivity emerges under stress, or why specific HLA alleles shape risk.
Cynthiya Shrestha, Holly M. Weisfelder, Thanh D. Do   +2 more
wiley   +1 more source

What Does the Shape Space of T Cell Epitopes Look Like?

Immunological Reviews, Volume 341, Issue 1, August 2026.
ABSTRACT Shape space is a decades‐old conceptual model of antibody–antigen interactions that underlies antigenic maps used to trace viral evolution. Here, we apply this concept to T cell receptors (TCRs) and the peptide–MHC complexes (pMHCs) that they recognize.
Franka Buytenhuijs, Gijs Schröder, Johannes Textor   +2 more
wiley   +1 more source